These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. A Randomized, Placebo-Controlled, Multiple-Ascending-Dose Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of the Soluble Guanylate Cyclase Stimulator Praliciguat in Healthy Subjects. Hanrahan JP; Wakefield JD; Wilson PJ; Mihova M; Chickering JG; Ruff D; Hall M; Milne GT; Currie MG; Profy AT Clin Pharmacol Drug Dev; 2019 Jul; 8(5):564-575. PubMed ID: 30422390 [TBL] [Abstract][Full Text] [Related]
3. Inhaled nitric oxide decreases pulmonary soluble guanylate cyclase protein levels in 1-month-old lambs. Thelitz S; Bekker JM; Ovadia B; Stuart RB; Johengen MJ; Black SM; Fineman JR J Thorac Cardiovasc Surg; 2004 May; 127(5):1285-92. PubMed ID: 15115984 [TBL] [Abstract][Full Text] [Related]
4. Regulation of soluble guanylyl cyclase activity by oestradiol and progesterone in the hypothalamus but not hippocampus of female rats. Reyna-Neyra A; Sarkar G; Etgen AM J Neuroendocrinol; 2007 Jun; 19(6):418-25. PubMed ID: 17388815 [TBL] [Abstract][Full Text] [Related]
5. Soluble guanylate cyclase stimulator praliciguat attenuates inflammation, fibrosis, and end-organ damage in the Dahl model of cardiorenal failure. Shea CM; Price GM; Liu G; Sarno R; Buys ES; Currie MG; Masferrer JL Am J Physiol Renal Physiol; 2020 Jan; 318(1):F148-F159. PubMed ID: 31608671 [TBL] [Abstract][Full Text] [Related]
10. [Nitric oxide. Potentiation of NO-dependent activation of soluble guanylate cyclase--(patho)physiological and pharmacotherapeutical significance]. Severina IS Biomed Khim; 2007; 53(4):385-99. PubMed ID: 18035720 [TBL] [Abstract][Full Text] [Related]
11. In vivo exposure to carbon monoxide causes delayed impairment of activation of soluble guanylate cyclase by nitric oxide in rat brain cortex and cerebellum. Hernández-Viadel M; Castoldi AF; Coccini T; Manzo L; Erceg S; Felipo V J Neurochem; 2004 Jun; 89(5):1157-65. PubMed ID: 15147508 [TBL] [Abstract][Full Text] [Related]
12. Dehydroepiandrosterone upregulates soluble guanylate cyclase and inhibits hypoxic pulmonary hypertension. Oka M; Karoor V; Homma N; Nagaoka T; Sakao E; Golembeski SM; Limbird J; Imamura M; Gebb SA; Fagan KA; McMurtry IF Cardiovasc Res; 2007 Jun; 74(3):377-87. PubMed ID: 17346686 [TBL] [Abstract][Full Text] [Related]
14. Nitric oxide-independent stimulation of soluble guanylate cyclase with BAY 41-2272 in cardiovascular disease. Boerrigter G; Burnett JC Cardiovasc Drug Rev; 2007; 25(1):30-45. PubMed ID: 17445086 [TBL] [Abstract][Full Text] [Related]
15. Age Impairs Soluble Guanylyl Cyclase Function in Mouse Mesenteric Arteries. Zhong C; Xu M; Boral S; Summer H; Lichtenberger FB; Erdoğan C; Gollasch M; Golz S; Persson PB; Schleifenbaum J; Patzak A; Khedkar PH Int J Mol Sci; 2021 Oct; 22(21):. PubMed ID: 34768842 [TBL] [Abstract][Full Text] [Related]
16. Soluble guanylyl cyclase and platelet function. Buechler WA; Ivanova K; Wolfram G; Drummer C; Heim JM; Gerzer R Ann N Y Acad Sci; 1994 Apr; 714():151-7. PubMed ID: 7912486 [No Abstract] [Full Text] [Related]
17. Should we Consider the Stimulation of Soluble Guanylyl Cyclase as Beneficial for Treating Pre-Capillary Pulmonary Hypertension? Alencar AKN Arq Bras Cardiol; 2022 Jun; 118(6):1067-1068. PubMed ID: 35703643 [No Abstract] [Full Text] [Related]
18. Stimulation of soluble guanylate cyclase slows progression in anti-thy1-induced chronic glomerulosclerosis. Wang Y; Krämer S; Loof T; Martini S; Kron S; Kawachi H; Shimizu F; Neumayer HH; Peters H Kidney Int; 2005 Jul; 68(1):47-61. PubMed ID: 15954895 [TBL] [Abstract][Full Text] [Related]